New drug may help MDS patients ditch blood transfusions
NCT ID NCT07319845
First seen Jan 08, 2026 · Last updated May 17, 2026 · Updated 21 times
Summary
This study tests an experimental drug called TAK-226 in about 27 Japanese adults with a bone marrow condition called myelodysplastic syndromes (MDS) who need regular blood transfusions. The goal is to see if TAK-226 can help them go without transfusions for at least 8 weeks. Participants will receive the drug and be followed for up to 6 years to monitor safety and long-term effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.